The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand’s pharmaceutical benefit package

There is increasing impetus to use pharmaceutical interventions, ie, ranibizumab or bevacizumab, for the treatment of particular macular diseases. This paper describes the evidence and decision-making of the National List of Essential Medicines Committee that recently announced the inclusion of beva...

Descripción completa

Detalles Bibliográficos
Autores principales: Anothaisintawee, Thunyarat, Leelahavarong, Pattara, Ratanapakorn, Tanapat, Teerawattananon, Yot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520463/
https://www.ncbi.nlm.nih.gov/pubmed/23248574
http://dx.doi.org/10.2147/CEOR.S37458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520463/
https://www.ncbi.nlm.nih.gov/pubmed/23248574
http://dx.doi.org/10.2147/CEOR.S37458

Ejemplares similares